SCHEMBL145291

SCHEMBL145291

[C]1=C[CH]C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8802218 0.59
SCHEMBL958835 0.54
SCHEMBL4175824 0.50
SCHEMBL2295963 0.47
SCHEMBL23908691 0.43
Hydrogen Sulfide SCHEMBL434423 0.35
SCHEMBL6559802 0.35
SCHEMBL33654 0.35
SCHEMBL3723878 0.35
SCHEMBL29889134 0.35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 964 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240182865-A1 VISIBLE LIGHT POLYMERIZATION OF POLYETHYLENE GLYCOL (PEG) HYDROGELS STEM PHARM, INCORPORATED 2024-06-06 US disclosed
US-11981703-B2 Polynucleotide constructs SIRIUS THERAPEUTICS, INC. (US) 2024-05-14 US disclosed
CN-117813281-A Continuous flow process for the production of cationic lipids 马克斯·普朗克科学促进学会 2024-04-02 CN disclosed
EP-4341241-A1 CONTINUOUS FLOW PROCESS FOR PRODUCTION OF CATIONIC LIPIDS Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2024-03-27 EP disclosed
WO-2023250427-A2 FORMULATIONS FOR MODULATING MYC EXPRESSION FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2023-12-28 WO disclosed
WO-2023250429-A2 COMBINATION THERAPIES COMPRISING MYC MODULATION FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2023-12-28 WO disclosed
US-20230381180-A1 SMALL MOLECULE MODULATORS OF KSR-BOUND MEK ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-11-30 US disclosed
US-20230321083-A1 Inhibitors of GPR174 and Uses Thereof OMEROS CORP (US) 2023-10-12 US disclosed
US-20230285556-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER OMEROS CORPORATION 2023-09-14 US disclosed
US-20230273228-A1 Diagnostic Method and Compounds for the Treatment of Infections Caused by a Pathogen SOLUTEX GC, S.L. (ES) 2023-08-31 US disclosed
EP-1244749-A2 MOBILITY-MODIFYING CYANINE DYES Applera Corporation (US) 2002-10-02 EP disclosed
US-20020102590-A1 Fluorescent nucleobase conjugates having anionic linkers PE CORPORATION (NY) (US) 2002-08-01 US disclosed
WO-2002030944-A2 FLUORESCENT NUCLEOBASE CONJUGATES HAVING ANIONIC LINKERS APPLERA CORPORATION (US) 2002-04-18 WO disclosed
US-6372907-B1 LABELLED RHODAMINE DYE-POLYPEPTIDE CONJUGATE, OR SALT THEREOF, COMPRISING RHODAMINE-TYPE PARENT XANTHENE RING SUBSTITUTED AT XANTHENE C-9 CARBON WITH SUBSTITUTED PHENYL RING APPTERA CORPORATION 2002-04-16 US disclosed
US-6348596-B1 NUCLEIC ACID HYBRIDIZATION ASSAYS; DNA SEQUENCE DETERMINATION PE CORPORATION (NY) 2002-02-19 US disclosed
WO-2001091758-A1 WATER-SOLUBLE AMIDE DERIVATIVES OF POLYENE MACROLIDES AND PREPARATION AND USES THEREOF INTRABIOTICS PHARMACEUTICALS, INC. (US) 2001-12-06 WO disclosed
EP-1141137-A1 WATER-SOLUBLE RHODAMINE DYES AND CONJUGATES THEREOF Applera Corporation (US) 2001-10-10 EP disclosed
WO-2001049790-A2 MOBILITY-MODIFYING CYANINE DYES APPLERA CORPORATION (US) 2001-07-12 WO disclosed
WO-2001032783-A1 WATER-SOLUBLE RHODAMINE DYES AND CONJUGATES THEREOF APPLERA CORPORATION (US) 2001-05-10 WO disclosed
US-6191278-B1 COMPRISING A RHODAMINE-TYPE PARENT RING HAVING ATTACHED TO THE XANTHENE C9 CARBON A PHENYL GROUP THAT IS SUBSTITUTED WITH CARBOXY OR SULFONATE GROUP, ONE TO THREE AMINOPYRIDINIUM GROUPS AND AN ALKYL- OR ARYLTHIO, AND OPTIONALLY OTHER GROUPS PE CORPORATION 2001-02-20 US disclosed